Chemotactic cytokines, known as chemokines, modulate the inflammatory response, wound healing, tumorigenesis, angiogenesis, and pathogen entry into cells. Chemokine subfamilies are denoted based upon the structural presentation of the first two cysteine residues as CXC or CC. Chemokines exert their effects by binding to seven-transmembrane-G protein-coupled receptors and transducing intracellular signals which include activation of serine and tyrosine kinases and mobilization of calcium. Chemokine receptors (CXCR or CCR, depending upon the subfamily of chemokines the receptors bind) are present on leukocytes, endothelial cells, epithelial cells, melanocytes, macrophages, and dendritic cells. Disregulation of chemokine/ chemokine receptor expression is associated with a number of disorders: chronic inflammatory diseases such as rheumatoid arthritis, ARDS, and psoriasis, sepsis, angiogenesis associated with tumorigenesis, squamous cell carcinoma and melanoma. So that they might better understand the mechanism by which CXC chemokines regulate the immune response, wound healing and cell growth, they have partially characterized signal transduction through the CXCR2 receptor for CXC chemokines and the events involved in desensitization and sequestration of CXCR2. To further explore the hypothesis that CXC chemokines acting through CXCR2 regulate important events of cell migration, cell growth, and wound healing, they propose to more completely characterize the signal transduction pathway through CXCR2 and explore in vitro and in vivo models involving expression of gain and loss of function CXCR2 receptors in keratinocytes. There are three aims: 1) to develop in vitro and in vivo models to examine the biological consequence of gain or loss of function of CXCR2 receptors in the epidermis during wound healing; 2) to characterize the events which occur in response to ligand binding to CXCR2 which facilitate homologous/heterologous cross desensitization and CXCR2 sequestration; and 3) to characterize the role of tyrosine phosphorylation of pyk2, src, and p130CAS in the cell motility responses mediated through CXCR2. Characterization of the events of signaling and receptor sequestration and desensitization will facilitate rationale drug design for disorders where sustained sensitivity to chemokines is essential for therapeutic efficacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034590-19
Application #
6350037
Study Section
Pathology B Study Section (PTHB)
Program Officer
Woodhouse, Elizabeth
Project Start
1983-04-01
Project End
2002-07-15
Budget Start
2001-02-01
Budget End
2002-07-15
Support Year
19
Fiscal Year
2001
Total Cost
$247,447
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Pellom Jr, Samuel T; Dudimah, Duafalia F; Thounaojam, Menaka C et al. (2017) Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget 8:8604-8621
Lavender, Nicole; Yang, Jinming; Chen, Sheau-Chiann et al. (2017) The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. BMC Cancer 17:88
Sai, Jiqing; Owens, Philip; Novitskiy, Sergey V et al. (2017) PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Clin Cancer Res 23:3371-3384
Saxon, Jamie A; Sherrill, Taylor P; Polosukhin, Vasiliy V et al. (2016) Epithelial NF-?B signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. Oncoimmunology 5:e1168549
Johnson, Douglas B; Estrada, Monica V; Salgado, Roberto et al. (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582
Vilgelm, Anna E; Johnson, Douglas B; Richmond, Ann (2016) Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol 100:275-90
Sai, Jiqing; Rogers, Matthew; Hockemeyer, Kathryn et al. (2016) Study of Chemotaxis and Cell-Cell Interactions in Cancer with Microfluidic Devices. Methods Enzymol 570:19-45
Duvall-Noelle, N; Karwandyar, A; Richmond, A et al. (2016) LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex. Oncogene 35:1122-33
Richmond, Ann; Yang, Jinming (2016) The role of NF-kB in modulating antitumor immunity. Oncoimmunology 5:e1005522

Showing the most recent 10 out of 74 publications